With the permission of Cellceutix Corporation, we have uploaded a video to YouTube that is the audio commentary from Mr. Ehrlich about the press release on their innovative compound KM-391 for the treatment of autism. OTC Showcase wishes to thank Cellceutix for the use of the audio.
Other articlesgo to homepage
MEDL Mobile Partner DJ Pauly D Nominated for Best App Ever Award $MEDL(0)Mobile app developer MEDL Mobile, Inc. (OTCBB:MEDL) reported that partner DJ Pauly D’s app “Beat That Boardwalk” has been nominated for the 2011 Best Music Game for Android at The Best App Ever Awards (http://bestappever.com/v/mzgm) by the popular app review site. MEDL Mobile Co-Founder Dave Swartz said, “We wanted to do something unexpected for DJ |
|
NexCore Healthcare Capital Leading Percentage Gainers on the OTCBB Today $NXHC(0)With one hour remaining before today’s closing bell, a look at today’s percentage gainers on the Over the Counter Bulletin Board: NexCore Healthcare Capital Corp. (OTCBB:NXHC) is up 483.09% to $0.20 on 9.1k in volume China Advanced Technology (OTCBB:CADT) is up 234.71% to $4.05 on 300k in volume AISYSTEMS, Inc. (OTCBB:ASYI) is up 147.06% to |
|
Platinum Studios and Mark Canton Partner for “Atlantis Rising” Film Series $PDOS(0)Platinum Studios Inc. (OTCBB:PDOS) and producer/Platinum Studios Board Member Mark Canton announced that they will be teaming-up to immediately begin work on bringing the Platinum Studios comic book “Atlantis Rising” into an ongoing franchise for the silver screen. The film is set against an undersea civilization that began over 10,000 years ago, and whose presence |
|
Cannabis Science Updates Show Cannabis Extracts Killing Skin Cancer $CBIS(0)Following news in December 2011 of a second cancer patient self-administering cannabis extract to combat basal cell carcinoma (skin cancer), Cannabis Science, Inc. (OTCBB:CBIS) reported today that it appears that the cannabis therapy has eradicated the cancer. The company stated that they are waiting for a full biopsy report to confirm that the cancer is |
|
Bebida Beverage Bringing Koma Unwind to New York City $BBDA(0)Relaxation Drink “Koma Unwind” will be available to people in the New York City area, according to manufacturer Bebida Beverage Company (Pink Sheets:BBDA). The company reported this morning that it has signed new agreements with S.K.I. Beer and All Star Imports to distribute the non-alcoholic drink throughout the NYC vicinity. S.K.I. will be rolling-out Koma |
|
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
1 comment
#1adminMarch 29, 2010, 2:12 pm
An article about this has also been posted on http://www.masshightech.com - The Journal of New England Technology.
Cellceutix autism study returns positive data
Beverly biopharmaceutical Cellceutix Corp. today reported positive results in an animal study of its autism compound, KM-391, which it acquired from an unspecified Indian university in a deal finalized in December.
Cellceutix (OTCBB:CTIX) said in a press release that in the 90-day animal study KM-391 was given orally to groups of rats at two dosage levels. “At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the ‘no treatment’ group and the ‘active control’ (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function.”
CFO Leo Ehrlich said that the next step in the research is to continue to synthesize quantities of KM-391 for use in toxicology studies, and that, if those studies are successful, any application for an investigational new drug application and clinical trial is at least a year away.
Cellceutix develops small molecules to treat cancer and inflammatory diseases. Earlier this month, Cellceutix signed a deal with Andover-based Formatech Inc. to formulate its compound Kevetrin for a Phase 1 study to treat resistant cancers.
Add your comment
Commenting is allowed only for registered users.